TX Digestive Disease Consultants

1. Intercept Pharmaceuticals, Inc. $1,497,645 164 payments
2. Takeda Pharmaceuticals U.S.A., Inc. $696,790 197 payments
3. Roche Products Limited $125,471 34 payments
4. Takeda Pharmaceuticals International, Inc. $95,040 2 payments
5. Genentech, Inc. $89,907 41 payments
6. AbbVie, Inc. $88,800 31 payments
7. Celgene Corporation $608 1 payment

1. 1011866 $1,029,934 89 payments
2. 1009742 $456,109 66 payments
3. An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk $254,371 21 payments
4. A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis ENTERPRET $171,655 20 payments
5. A Randomized Evaluation of Changes in Anxiety and Depression, Patient Reported Outcomes, Service Utilization and Patient Satisfaction Scores in IBD Patients Comparing Standard of Care Medical Treatment to Structured Psychosocial Care in Addition to Standa $95,040 2 payments
6. ENTYVIO Outcomes in Real-World Bio-naive Ulcerative Colitis and Crohns Disease Patients EVOLVE $81,000 4 payments
7. Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance $71,674 23 payments
8. A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis (Enterpret) $56,521 5 payments
9. A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis (Enterpret) $55,244 61 payments
10. Crohn S Disease Program Ole $53,797 11 payments

1. Other $634,373 50 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.